DNA methylation

Nucleix Demonstrates Potential of its PCR EpiCheck® Assay to Accurately Differentiate Between Small Cell Lung Cancer (SCLC) Subtypes

Retrieved on: 
Thursday, April 4, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Oncology, Diagnosis, PCR, Plasma, Carcinoma, Cancer cell, Protocol, Biomarker, DNA, Classification, University, MD Anderson Cancer Center, DNA methylation, AACR, Liquid biopsy, SCLC, Medical imaging

Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from a pilot study demonstrating the potential of a simple PCR assay based on EpiCheck® technology to accurately differentiate between small cell lung cancer (SCLC) subtypes.

Key Points: 
  • Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from a pilot study demonstrating the potential of a simple PCR assay based on EpiCheck® technology to accurately differentiate between small cell lung cancer (SCLC) subtypes.
  • The Company is presenting the data in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, April 5-10.
  • The 13-marker PCR assay developed for this pilot study stemmed from data from a recent study published in Cancer Cell demonstrating the detection of SCLC using DNA methylation in plasma samples from heavy smokers, yielding a sensitivity of 94% and specificity of 95%.
  • In the data being presented at AACR, the 13-marker PCR assay correctly classified 97% of the SCLC tissue samples in a blinded cohort.

DNA Methylation Detection Technology Market Research 2024 - Global Forecast to 2033 Featuring Prominent Players - Thermo Fisher Scientific, Illumina, QIAGEN, Zymo Research, and Agilent Technologies - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Genetics, Health, Diagnosis, PCR, Growth, Drug discovery, Thermo Fisher Scientific, Biomarker, Research, DNA, Competitive landscape, Real-time, Microarray, Cancer, Software, DNA methylation, Agilent Technologies, DSM-IV codes, QIAGEN, MSP, Prognosis, Marketing, Medicine, Fine chemical

The global DNA methylation detection technology market is projected to experience substantial growth over the forecast period 2023-2033.

Key Points: 
  • The global DNA methylation detection technology market is projected to experience substantial growth over the forecast period 2023-2033.
  • In the DNA methylation detection technology market, several key players dominate the landscape with their diverse range of products and solutions.
  • Thermo Fisher Scientific, Illumina, Inc. QIAGEN, Zymo Research Corporation, and Agilent Technologies, Inc. are among the prominent market players offering innovative tools and platforms for DNA methylation analysis.
  • The global DNA methylation detection technology market can be considered to be in the mature growth stage of its lifecycle.

EpiMedTech Global to Present Revolutionary Epigenetics Research at MedInvest Biotech & Pharma Investor Conference

Retrieved on: 
Tuesday, April 2, 2024
Conference, Gene expression, Syndrome, FRSC, DNA, Cancer, DNA methylation, Embryo, FCAHS, HKG, Ageing, Vaccine

The presentation will spotlight groundbreaking advancements in DNA methylation and its significant potential in transforming global healthcare through early disease detection.

Key Points: 
  • The presentation will spotlight groundbreaking advancements in DNA methylation and its significant potential in transforming global healthcare through early disease detection.
  • DNA methylation, a critical process in epigenetic signaling, acts as a sophisticated regulatory mechanism, controlling gene expression without altering the DNA sequence itself.
  • "EpiMedTech Global is at the forefront of leveraging DNA methylation for early disease detection, aiming to bridge the vast gap between the potential of epigenetic research and its current clinical application," said Prof. Szyf.
  • Join us at MedInvest to discover how EpiMedTech Global is paving the way for a future where early detection and prevention are within reach for everyone, everywhere.

DNA Methylation Detection Technology Markets, 2033 - Intensified Competition, Increasing Adoption, PCR Dominates

Retrieved on: 
Saturday, March 30, 2024
Diagnosis, PCR, Health, Growth, Biotechnology, Drug discovery, Thermo Fisher Scientific, Biomarker, Research, DNA, Competitive landscape, Real-time, Microarray, Cancer, Software, DNA methylation, Agilent Technologies, DSM-IV codes, QIAGEN, MSP, Prognosis, Marketing, Medicine, Fine chemical

In the DNA methylation detection technology market, several key players dominate the landscape with their diverse range of products and solutions.

Key Points: 
  • In the DNA methylation detection technology market, several key players dominate the landscape with their diverse range of products and solutions.
  • Based on technology, the PCR segment accounted for the largest share of the global DNA methylation detection technology market in FY2022.
  • Moreover, PCR is expected to maintain its dominance in the global DNA methylation detection technology market by technology due to its widespread adoption, versatility, and reliability.
  • Based on application, diagnostic research accounted for the largest share of the global DNA methylation detection technology market in FY2022, primarily due to clinicians' increasing focus on utilizing DNA methylation analysis for clinical diagnostics.

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheime

Retrieved on: 
Friday, March 1, 2024
L-DOPA, MCP1, Chemokine, Alzheimer's disease, Phagocytosis, Political moderate, Principal, MDS-UPDRS, Cholesterol, Insulin, Inflammation, Part, ADAS, Plaque, Conference, Placebo-controlled study, Parkinson's disease, Diabetes, Carbidopa/levodopa, Pharmacokinetics, Digestion, Disease, DNA methylation, DNA, Brain, Pharmaceutical industry

CARSON CITY, Nev., March 01, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced two upcoming presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024 (AD/PD™ 2024) to be held March 5-9, 2024 in Lisbon, Portugal.

Key Points: 
  • These findings complement previously reported improvement in motor symptoms in patients treated with NE3107 and demonstrate potential intrinsic, levodopa-enhancing activity of NE3107 that is consistent with data from animal models.
  • NE3107-treated patients experienced a significant improvement of -2.4 points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson’s Disease, whereas placebo patients experienced a worsening of +1.0 points (p=0.0159).
  • Sleep/fatigue domain improvements correlated with motor score improvements (r=0.51; p=0.0259).
  • More patients on NE3107 had improvements in the NMSS sleep/fatigue domain, while more patients on placebo worsened.

Wistar Scientists Discover Link Between Leaky Gut and Accelerated Biological Aging

Retrieved on: 
Friday, February 23, 2024
Methylation, Dysbiosis, Culture, Penn Center, Health, Bacteria, University, Subtypes of HIV, Life Length, Wistar Institute, Bangladesh Technical Education Board, Ileum, Infection, NIH, AIDS, Glass, Metabolomics, Nucleotide, DSM-IV codes, Biomedical Research, HIV/AIDS research, Wistar, University of Pittsburgh, DNA, Immune system, National Institutes of Health, Leiden University Medical Center, Weill Cornell Medicine, Hannum, Research, Inflammation, Blood, Ageing, Cancer, Cell biology, Microbiome, Rush University, HIV, DNA methylation, Vaccine

Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.

Key Points: 
  • Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.
  • A prime suspect in this aging puzzle is the gut microbiome and its potential leakage into the bloodstream.
  • The Abdel-Mohsen lab investigates how gut leakage can impact the immune system and lead to chronic inflammation, which may accelerate aging.
  • Their analysis revealed a significant connection between disrupted gut microbiomes, increased intestinal permeability (leaky gut), and faster biological aging.

Fujirebio Europe Expands Its Portfolio With Introduction of the Innovative PreCursor-M AnoGYN assay (RUO) for Methylation Testing in Anal Specimens

Retrieved on: 
Tuesday, March 5, 2024
Oncology, Medical Supplies, Health, Medical Devices, Research, Science, Biotechnology, Methylation, Cervical cancer, Woman, ASCL1, Dysplasia, Triage, Partnership, Multiple endocrine neoplasia, Test management, Human papillomavirus infection, Fujirebio, Risk, SCC, Biomarker, RUO, Incidence, Patient, Carcinoma, Carcinogenesis, Gene, HPV, HSIL, Host, Anal cancer, Lithium, DNA methylation, DNA, IVD, Cancer, CIN, Vaccine

Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.

Key Points: 
  • Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.
  • In analogy with cervical cancer screening, the screening and treatment of HSIL to prevent anal cancer in high-risk groups are under debate.
  • Host cell deoxyribonucleic acid methylation markers for the detection of high-grade anal intraepithelial neoplasia and anal cancer.
  • Analytical validation and diagnostic performance of the ASCL1/ZNF582 methylation test for detection of high-grade anal intraepithelial neoplasia and anal cancer.

Rejuvenate Bio Announces Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in the Journal Cellular Reprogramming

Retrieved on: 
Thursday, February 22, 2024
Research, Genetics, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Ageing, Mouse, KLF4, Notifiable disease, Vivisection, Stem cell, Scalp, Biomarker, OSK, Keratinocyte, Heart, Male, Yamanaka, AAV, DNA methylation, DNA, Vaccine

The study, titled " Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice ," reveals promising advancements in combating age-related diseases and extending lifespan through cellular rejuvenation.

Key Points: 
  • The study, titled " Gene Therapy-Mediated Partial Reprogramming Extends Lifespan and Reverses Age-Related Changes in Aged Mice ," reveals promising advancements in combating age-related diseases and extending lifespan through cellular rejuvenation.
  • While aging cannot be prevented, interventions targeting cellular processes offer potential for mitigating its impact on health and lifespan in the elderly.
  • Rejuvenate Bio's research focuses on partial reprogramming using the Yamanaka factors, specifically OCT4, SOX2, and KLF4 (OSK), to reverse age-related changes.
  • These results may have important implications for the development of partial reprogramming interventions to reverse age-associated diseases in the elderly population.”

Wasatch Biolabs Launches Proprietary Targeted DNA Methylation Sequencing Service for Researchers and Healthcare Providers

Retrieved on: 
Tuesday, February 13, 2024
Methylation, Nanopore, A-DNA, Oxford Nanopore Technologies, WBL, Cancer, Drug development, Entrepreneurship, RNA, Gene expression, Nanopore sequencing, Disease, PCR, DNA methylation, Research, DNA, AMR, Fine chemical

HEBER CITY, Utah, Feb. 13, 2024 /PRNewswire/ -- Wasatch Biolabs (WBL) , a subsidiary of Renew Biotechnologies and a certified Oxford Nanopore Technologies' laboratory, launches a proprietary Targeted DNA Methylation Sequencing Service for researchers and clinical service providers.

Key Points: 
  • HEBER CITY, Utah, Feb. 13, 2024 /PRNewswire/ -- Wasatch Biolabs (WBL) , a subsidiary of Renew Biotechnologies and a certified Oxford Nanopore Technologies' laboratory, launches a proprietary Targeted DNA Methylation Sequencing Service for researchers and clinical service providers.
  • The DNA methylation service is being released among WBL's first wave of Oxford Nanopore-based sequencing services, and is the company's first big step toward making Oxford Nanopore sequencing and the power of epigenetics more accessible to researchers and healthcare providers.
  • Bisulfite sequencing, which involves chemical treatment of DNA with sodium bisulfite and PCR amplification, remains the de facto standard for DNA methylation analysis.
  • In addition to its proprietary DNA methylation sequencing service, WBL also offers other Oxford Nanopore assay-based sequencing services, including whole genome, cDNA, and RNA sequencing, among others, to researchers and clinical service providers.

Previse Unveils New Headquarters and State-of-the Art Lab to Meet Growing Demand for Esopredict Test

Retrieved on: 
Thursday, February 8, 2024
DNA methylation, Growth, Heart, Health, Physician, GI, DNA, Risk, Patient, Research, CLIA

BALTIMORE, Feb. 8, 2024 /PRNewswire/ -- Previse, a company focused on improving health for patients with gastrointestinal diseases, today announced that it has relocated its headquarters and opened a new state-of-the-art CLIA high complexity laboratory in Baltimore, MD to meet demands for the company's first clinically available test, Esopredict.

Key Points: 
  • Esopredict, the first and only commercially available test that assesses DNA methylation levels to risk stratify patients with esophageal pre-cancer, analyzes epigenetic biomarkers to provide GI physicians and their patients personalized predictive data to guide patient treatments and endoscopic surveillance.
  • The expansion of Previse's CLIA lab increases its testing capacity to serve an additional 10,000 patients annually, which is a significant stride towards improving access to precise and expeditious diagnostic services.
  • Daniel Lunz, Co-founder and CEO, commented on the growth, "Our new headquarters and the expanded lab reflect our unwavering commitment to enhancing the value provided to physicians and patients, which is at the heart of our innovation-driven ethos."
  • The move will also expand the research capabilities of Previse, as the company develops additional innovative technologies including minimally invasive tests for upper GI disease detection and monitoring and to further service ongoing research partnerships.